Techniques for Improving Ultrasound Visualization of Biopsy Markers in Axillary Lymph Nodes
How to cite this article: Lee C, Zhou C, Hyde B, Song P, Hangiandreou N. Techniques for Improving Ultrasound Visualization of Biopsy Markers in Axillary Lymph Nodes. J Clin Imaging Sci 2020;10:21.
Biopsy markers are often placed into biopsy-proven metastatic axillary lymph nodes to ensure later accurate node excision. Ultrasound is the preferred imaging modality in the axilla. However, sonographic identification of biopsy markers after neoadjuvant therapy can be challenging. This is due to poor conspicuity relative to surrounding parenchymal interfaces, treatment-related alteration of malignant morphology during neoadjuvant chemotherapy, or extrusion of the marker from the target. To the authors’ knowledge, the literature provides no recommendations for ultrasound scanning parameters that improve the detection of biopsy markers. The purpose of this manuscript is 3-fold: (1) To determine scanning parameters that improve sonographic conspicuity of biopsy markers in a phantom and cadaver model; (2) to implement these scanning parameters in the clinical setting; and (3) to provide strategies that might increase the likelihood of successful ultrasound detection of biopsy markers in breast imaging practices.
Materials and Methods:
An ex vivo study was performed using a phantom designed to simulate the heterogeneity of normal mammary or axillary soft tissues. A selection of available biopsy markers was deployed into this phantom and ultrasound (GE LOGIQ E9) was performed. Scanning parameters were adjusted to optimize marker conspicuity. For the cadaver study, the biopsy markers were deployed using ultrasound guidance into axillary lymph nodes of a female cadaver. Adjustments in transducer frequency, dynamic range, cross-beam (spatial compound imaging), beam steering, speckle reduction imaging, harmonic imaging, colorization, and speed of sound were evaluated. Settings that improved marker detection were used clinically for a year.
Sonographic scanning settings that improved biopsy marker conspicuity included increasing transducer frequency, decreasing dynamic range, setting cross-beam to medium hybrid, turning on beam steering, and setting speckle reduction imaging in the mid-range. There was no appreciable improvement with harmonic imaging, colorization, or speed of sound.
On a currently available clinical ultrasound scanning system, ultrasound scanning parameters can be adjusted to improve the conspicuity of biopsy markers. Overall, optimization requires a balance between techniques that clinically increase contrast (dynamic range, harmonic imaging, and steering) and those that minimize graininess (spatial compound imaging, speckle reduction imaging, and steering). Additional scanning and procedural strategies have been provided to improve the confidence of sonographic detection of biopsy markers closely associated with the intended target.
When it was determined that the false-negative rate of sentinel lymph node surgery in patients with node-positive breast cancer (T0-4, N1-2, and M0 [TNM classification]) could be reduced by identifying and resecting the marked positive axillary lymph node, pre-operative localization of the marked node became the practice at many medical facilities. Pre- operative localization of the marked node can be challenging, particularly after positive treatment response to neoadjuvant therapy. At this time, the positive axillary lymph node often becomes mammographically or sonographically occult, leaving only the biopsy marker in or near the site of the node.
Biopsy markers are made of either titanium, stainless steel, an alloy of titanium, and nickel, or ceramic and typically range from 1 mm (smallest dimension) to 8 mm (greatest dimension) [Table 1]. A myriad of marker conformations is commercially available, each describing visibility on ultrasound (US), mammograms, and magnetic resonance imaging (MRI), as well as minimal soft-tissue migration of the marker once it has been deployed.[2-4]
|Biopsy marker||Measured size (mm × mm)||Manufacturer information|
|O||1 ×2||SenoRx, Inc., Tempe, AZ, USA|
|Cylinder||1 ×3||Trimark, Hologic Inc., Marlborough, MA|
|Top hat||1 ×2||SecurMark, Hologic Inc., Marlborough, MA|
|Coil||1 ×2||Mammotome HydroMARK, Leica Biosystems, Wetzlar, Germany
SenoMark UltraCor, Bard Biopsy, Tempe, AZ, USA
|U||1 ×2–3||MammoMARK/CorMARK, Leica Biosystems, Wetzlar, Germany|
|Ribbon||1 ×3||Bard UltraClip, Tempe, AZ, USA|
|U||3 ×4||Tumark Professional U, Somatex Medical Technologies, Teltow, Germany|
|Vision||3 ×7||Tumark Vision, Somatex Medical Technologies, Teltow, Germany|
|Eye||2 ×8||Tumark Eye, Somatex Medical Technologies, Teltow, German|
Despite mammographic conspicuity of all metallic biopsy markers, US is the imaging modality of choice in the axilla. Aside from using ionizing radiation, a mammographic approach can be technically challenging in the axilla, particularly when the marked positive node must be included between the mammographic plates. For many patients, this can be an uncomfortable position, making it difficult to perform mammographic- or tomosynthesis-guided localization. If the marked positive lymph node is located very far posteriorly, a mammographic technique may be prohibitive. For these reasons, breast radiologists prefer US- guided localizations of the marked lymph node. However, confidently identifying the marked positive lymph node by US after neoadjuvant chemotherapy can be challenging, if not impossible.
Two main factors contribute to the difficulties in detecting the marked lymph node after neoadjuvant chemotherapy. The first factor is poor marker conspicuity due to surrounding echogenic Cooper’s ligaments, dense fibroglandular tissue, or shadowing tissue interfaces related to the heterogeneity of the breast parenchyma. The other factors are suspected extrusion or migration of the marker away from the positive lymph node as the lymph node normalizes during neoadjuvant chemotherapy. Both factors uniquely contribute to the complexity of US detection of the positive lymph node at the time of pre-operative localization.
Very little, if any, literature is available that describes ways to optimize sonographic visualization of the marker in an axillary lymph node, particularly after neoadjuvant chemotherapy. The purpose of this manuscript is to optimize sonographic scanning parameters for marker conspicuity in a phantom and cadaver model. A reflection on more than a year of clinically implementing these optimization trends is provided. Finally, a few helpful strategies are suggested, which might increase the likelihood of successfully identifying the marked lymph node by US in clinical practice.
MATERIALS AND METHODS
This study was approved by our Institutional Review Board and was compliant with the Health Insurance Portability and Accountability Act (HIPAA). The ex vivo section of this study involved (1) designing a reproducible phantom model that mimics normal mammary and axillary soft tissue and (2) sonographically evaluating biopsy markers used in our breast radiology practice, first in the phantom model and then in the cadaver model. The biopsy markers or clips used in this investigation were either expired or opened but never used; these included O-, cylinder-, top hat-, coil-, and U-shaped markers [Table 1]. The O-shaped and U-shaped markers are associated with resorbable packing or embedding material; the coil-shaped clip with biodegradable hydrogel polymer; and the top hat-shaped marker with resorbable netting. Such surrounding material was removed, and the metallic clips were isolated for the ex vivo studies to simulate what generally remains in patients after months of neoadjuvant chemotherapy.
Eight clinically available US scanning parameters, frequency, dynamic range, cross-beam setting, beam steering, speckle reduction processing, harmonic imaging, colorization, and speed of sound, were adjusted to optimize conspicuity of the clip on a GE LOGIQ E9 US unit (GE Healthcare Inc., Wauwatosa, WI USA). The broad-spectrum linear matrix array transducer (ML6–15) is the probe most often used for breast USs, and this was the probe used for the cadaver study. For the phantom study, the 9L probe was also used. Time gain compensation, focusing, and output power were variably adjusted as in the clinical setting.
The phantom study began with the design and development of a phantom model that simulates mammary parenchyma on US. Grapefruit pulp provided heterogeneity suggestive of background breast parenchyma that would make finding a biopsy marker challenging [Figure 1]. Grapefruit pulp is difficult to maintain in form and difficult to preserve. Therefore, the recipe for a standard gel phantom was modified to include talcum powder or flour of varying amounts. The phantom was created with layers of molded gel (some with and without talcum powder or flour) and variably thick layers of paper towels/tissue [Figure 2]. A further modification which wrapped the gel pieces with cellophane and then stacked them randomly in a mold resulted in similar imaging features.
The O-, cylinder-, top hat-, coil-, and U-shaped markers were placed into one of the phantoms and scanned with an ML6–15 MHz probe using default settings that simulate the clinical environment.
In collaboration with colleagues in the anatomy laboratory, a female cadaver with axillary lymph nodes was identified. The ribbon- and U-shaped markers were percutaneously deployed into the axillary nodes, and two radiologists (CL and BH) starting with the default biopsy preset mode adjusted the eight US scanning parameters described earlier until conspicuity of the marker was deemed optimal by consensus.
In the phantom study, the O- and U-shaped markers were essentially inconspicuous [Figure 3] with the O-shaped marker marginally more conspicuous than the U-shaped one. For the cadaver study, the adjustments to the eight scanning parameters of the default settings are summarized in Table 2, where additional figures are referenced.
|Parameter||Default biopsy mode setting||Adjustment from default biopsy mode||Preference||Example|
|Frequency||11 MHz||9 MHz, 13 MHz, 15 MHz||Higher frequencies||Figure 4|
|Dynamic range||72 dB||41 dB, 48 dB, 69 dB||69 dB||Figure 5|
|Cross-beam (spatial compound imaging)||Low mean||Medium hybrid||Medium hybrid||Figure 6|
|Beam steering||Disabled||Enabled and in direction perpendicular to orientation of the marker||On||Figure 7|
|Speckle reduction imaging||4||0, 3, 5||3||Figure 8|
|Harmonic imaging||Disabled||Enabled||No preference||Figure 9|
|Speed of sound||1540 m/s||1420 m/s||No preference||None|
|Color||Gray scale||Tinted||No preference||None|
Identifying marked axillary lymph nodes for radioactive I-125 seed localization after neoadjuvant therapy can be challenging for several reasons. These include altered morphology (normalization) of the treated lymph node, suspected extrusion of the marker from the lymph node, and poor sonographic conspicuity of the markers. This study reviewed modifications of several widely available scanning parameters during US evaluation of marked axillary lymph nodes to improve marker conspicuity and confidence of marker detection. Although the availability of cadavers with axillary lymph nodes only allowed for limited evaluations, it did provide insight and the realization that some of the expected optimization trends were occasionally not the ones preferred. While the preference of higher frequencies, for example, made theoretical sense based on physics, other adjustments were more counter intuitive. For instance, in this study, there was no preference when using harmonic imaging. This seems to support studies which have shown that harmonic imaging provided limited value in needle visualization in the breast.[6,7] There is also an interplay between dynamic range, spatial compound imaging, speckle reduction imaging, and harmonic imaging that need to be explored for each case, given the variations in depth of the marked lymph node, the type of marker, and the conspicuity of the positive lymph node after neoadjuvant chemotherapy. For the cadaver model, sonographic optimization techniques included increasing transducer frequency, slightly decreasing dynamic range, setting cross-beam to medium hybrid, turning on beam steering, and setting speckle reduction imaging to mid-range. Different vendors have slight variations that instantiate the parameters tested, and these will need to be optimized accordingly.
A limitation of this study is that any material surrounding the metallic marker was removed. For some markers, the surrounding material may be the very feature that makes it sonographically conspicuous. The biodegradability of materials surrounding the metallic components varies, so markers identified indirectly by said materials may or may not be detectable months after neoadjuvant chemotherapy.
After more than a year of implementing these US techniques optimized for marker detection in the clinical setting, successful detection seems to be a balance between techniques that increase contrast and those that minimize graininess. Vocal fremitus, elastography, Doppler, and power reduction provided no additional improvement in marker detection. However, a few strategies seem to improve the likelihood of detecting or confirming the marked positive node by US, and it starts from the time of the fine-needle aspiration and marker placement [Table 3].
|At the time of fine-needle aspiration or marker placement when the abnormal lymph node is easily detected, or anytime during follow-up US when the marked node is well seen before pre-operative localization||At the time of pre-operative localization|
|1. Field of view
Include a cine clip of the abnormal lymph node with a larger field of view or with virtual convex, paying particular attention to include adjacent anatomic landmarks; more than one orientation may be helpful. e aim is to ensure the reproducibility of scanning orientation and transducer placement.
Consider reporting or annotating on an image frame the location of the marked lymph node relative to a unique skin finding (e.g., freckle, mole, and skin tag) or distance from the nipple.
3. Indelible skin mark
Consider making a tattoo dot at the location of the lymph node. is can be performed as a clean technique with a drop of SteriTatt Black Ink Dropper (Klarity Medical Products, Newark, OH, USA) on the skin, followed by gentle insertion of a 21G or 20G needle through the ink and just under the skin surface. e remainder of the ink is wiped away, leaving a small tattoo dot.
Ask the patient if she is similarly positioned compared to previous axillary ultrasound examinations; consider adjusting the patient’s arm during the scan.
2. Transducer pressure
Consider increasing transducer pressure; this is particularly helpful to bring deeper marked nodes into the near-field.
3. Procedural confirmation
At the time of obtaining local anesthesia, attempt to inject lidocaine or sterile saline immediately aroundthe suspected marker, or attempt to tap on the marker with the needle tip.
When US is unsuccessful in identifying a marked axillary node, alternative imaging guidance such as CT or tomosynthesis can be considered.[8-10] A limited selection of biopsy markers with similar imaging characteristics was used for the cadaver model. There are a variety of biopsy markers on the market, and a large number have been reviewed as options for localization of axillary lymph nodes. Hygroscopic markers such as the HydroMARK coil-shaped markers (Mammotome HydroMARK, Norderstedt, Germany) seemed hopeful for improving sonographic detection, but aside from challenging detectability over time and migration or extrusion of the marker, there were initially, at our institution, concerns of false positives at the time of surgical pathology. In addition, non-wire localization techniques continue to explore their roles as biopsy markers to potentially obviate the localization step; these techniques include non-radioactive signaling sources such as iron particles (Magseed, Sentimag, Leica Biosystems, Wetzlar, Germany), radar (Savi Scout, Cianna Medical, Aliso Viejo, CA, USA), and radiofrequency tagging (LOCalizer, Faxitron, Tucson, AZ, USA).
In the meantime, non-ionizing features, patient comfort, and costs make US the preferred imaging modality for identifying a marked axillary lymph node. There are several currently available US scanning parameters that can be explored and tweaked to improve the conspicuity of the marked node, and it may take extra time to determine the optimal setting for each case. In addition, there are also clinical strategies that can be taken to improve the chances of detecting the marked positive lymph node.
Ultrasound scanning parameters can be adjusted to improve the conspicuity of biopsy markers. Overall, optimization requires a balance between techniques that increase contrast (dynamic range, harmonic imaging, and steering) and those that minimize graininess (spatial compound imaging, speckle reduction imaging, and steering). Additional scanning and procedural strategies can improve the confidence of sonographic detection of biopsy markers associated with the intended target.
The authors would like to acknowledge Rebecca L. Higgins, RT, RDMS, and Emily Smith, RVT, RDMS, for their assistance with US scanning parameter adjustments and insight, and Lyndsay Viers, M.D., for her efforts and assistance with obtaining IRB approval.
The authors would also like to acknowledge the assistance and support of Karen Mills, CST, Terry Regnier, and Shaun Heath from the Department of Anatomy. Our sincerest gratitude and respect go to the generosity and hopes of patients who donate their bodies for the advancement of medical practice.
Declaration of patient consent
Patient’s consent not required as there are no patients in this study.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.